- PR Newswire•7 days agoTheratechnologies Announces Comparative PK Data on the Intramuscular and Intravenous Administration of the Monoclonal Antibody and Long-Acting Investigational Antiretroviral Ibalizumab
MONTREAL, Feb. 15, 2017 /PRNewswire/ -- Theratechnologies Inc. (Theratechnologies) (TH.TO) announced today that pharmacokinetics (PK) and pharmacodynamics (PD) data comparing the intramuscular (IM) with the intravenous (IV) administration of ibalizumab were presented at the annual Conference on Retroviruses and Opportunistic Infections (CROI) 2017. The PK and PD of two doses of ibalizumab, 800 mg bi-weekly and 2000 mg every 4 weeks, administered IM were evaluated under study TMB-121. This data was compared to the PK and PD data of similar doses of ibalizumab administered IV from a previous study.
- Marketwired•7 days agoTheratechnologies Announces Comparative PK Data on the Intramuscular and Intravenous Administration of the Monoclonal Antibody and Long-Acting Investigational Antiretroviral Ibalizumab
Theratechnologies Inc. announced today that pharmacokinetics and pharmacodynamics data comparing the intramuscular with the intravenous administration of ibalizumab were presented at the annual Conference ...
- Accesswire•8 days agoResearch Reports Initiated on Healthcare Stocks Theratechnologies, Concordia International, Aurinia Pharmaceuticals, and Cardiome Pharma
LONDON, UK / ACCESSWIRE / February 15, 2017 / Active Wall St. announces the list of stocks for today's research reports. Pre-market the Active Wall St. team provides the technical coverage impacting selected ...
TH.TO : Summary for THERATECHNOLOGIES - Yahoo Finance
Theratechnologies Inc. (TH.TO)
Toronto - Toronto Delayed Price. Currency in CAD
Add to watchlist
|Day's Range||3.81 - 4.14|
|52 Week Range||1.26 - 4.29|
|PE Ratio (TTM)||1,017.50|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|